Sökresultat

IgA nephropathy (IgAN) and Henoch-Schönlein purpura (HSP) are diseases characterized by IgA deposits in the kidney and/or skin. Both may arise after upper respiratory tract infections, but the pathogenic mechanisms governing these diseases remain unclear. Patients with IgAN (n = 16) and HSP (n = 17) were included in this study aimed at examining whether IgA-binding M proteins of group A streptococ

Complement C2 deficiency (C2D) is associated with immunological diseases and increased susceptibility to invasive infections caused by encapsulated bacteria such as Neisseria menigitidis. In this study we evaluate the immunogenicity of vaccination against N. menigitidis in C2D. C2D patients (n=22) and controls (n=52) were given a tetravalent meningococcal polysaccharide vaccine. Serum bactericidal

Small synthetic ligands for protein purification have become increasingly interesting with the growing need for cheap chromatographic materials for protein purification and especially for the purification of monoclonal antibodies (mAbs). Today, Protein A-based chromatographic resins are the most commonly used capture step in mAb down stream processing; however, the use of Protein A chromatography

Transplantation of allogeneic embryonic neural tissue is a potential treatment for patients with Parkinson's and Huntington's diseases. The supply of human donor tissue is limited, and alternatives such as the use of animal (e.g., porcine) donor tissue are currently being evaluated. Before porcine grafts can be used clinically, strategies to prevent neural xenograft rejection must be developed. Kn

Tissue factor pathway inhibitor-2 (TFPI-2) has previously been characterized as an endogenous anticoagulant. TFPI-2 is expressed in the vast majority of cells, mainly secreted into the extracellular matrix. Recently we reported that EDC34, a C-terminal peptide derived from TFPI-2, exerts a broad antimicrobial activity. In the present study, we describe a previously unknown antimicrobial mode of ac

Introduction: Recent haemophilia treatment advances include new recombinant FVIII (rFVIII) products with improved pharmacokinetic (PK) properties that aim to reduce the burden of prophylaxis. These treatments are commonly referred to as extended half-life rFVIII products (EHL rFVIII). There is no uniform definition of what constitutes an EHL rFVIII. Such a definition would help physicians, patient

Background: Nigeria is a major contributor to the global malaria burden. The genetic diversity of malaria parasite populations as well as antibody responses of individuals in affected areas against antigens of the parasite can reveal the transmission intensity, a key information required to control the disease. This work was carried out to determine the allelic frequency of highly polymorphic Plas

It has previously been shown that sera from multiparous women have increased levels of anti-idiotypic antibodies specific for anti-HLA molecules. γ-Globulins prepared from these sera may be superior to commercial preparations of intravenous γ-globulin (IVIg) for inhibiting HLA alloimmunization. To test this, F(ab′)2 fragments prepared from either commercial IVIg or from the sera of men or multipar

Of 30 bacterial species tested 18 stimulated DNA synthesis in human blood lymphocytes. The maximum response was after 3-4 days of culture suggesting a mitogenic effect. This was confirmed by the induction of polyclonal antibody production shown by a plaque assay. Most bacterial species increased the DNA synthesis in B-enriched lymphocytes and unseparated lymphocytes but had negligible activity on

Antimicrobial peptides (AMPs) are evolutionarily ancient molecules. They are essential innate immune response molecules that protect organisms from invading pathogens. Tissue factor pathway inhibitors (TFPI-1 and TFPI-2) C-terminal derived peptides exert host defense mechanisms against microbes. Studies showed that in human plasma, C-terminal TFPI-1 and -2 derived peptides mediate bacterial killin

Institutionen för handelsrätt Uppd: 2024-06-20 Tentamensschema februari 2024 - augusti 2024 Datum Kurskod Kursnamn Tid Lokal Tors 1 feb HARG06 Arbetsrätt II, Dugga 8-10 MA9 Ons 7 feb HARN53 Trade, Investment and Sustainability 8-13 EC2:063 HARN54 Intellectual Property and Trade Ons 28 feb HARA71 Kommersiella avtal och köp 8-13 MA8 HARG15 Compliance och risk i affärslivet HARG03 Kommersiell avtalsr

https://www.ehl.lu.se/sites/ehl.lu.se/files/2024-06/Tentaschema%20VT%202024%20%20februari%20-%20augusti%202024%20extern%20hemsida%202024-06-20.pdf - 2026-05-17

LönestegarLönestegar exklusive lönebikostnader (LBK) och overhead (OH). Dokumenten nedan öppnas i ny flik.Lönestege - Doktorander som påbörjat utbildning före 1 augusti 2023 (PDF 65 KB)Lönestege – Doktorander som påbörjat utbildning från och med 1 augusti 2023 (PDF 72 KB)Rekommenderad ingångslön amanuenser (PDF 48 kB)Rekommenderad ingångslön postdoktor, biträdande forskare, laboratorieforskare (PD

https://www.intramed.lu.se/organisation-och-styrning/ekonomi/nyttiga-uppgifter-till-ansokningar - 2026-05-16

https://www.ehl.lu.se/om-ekonomihogskolan/kontakta-oss/julhelgens-oppettider - 2026-05-15

Arbetsrehabilitering Efterfrågan på evidensbaserade insatser har ökat markant i Sverige och Individual Placement and Support (IPS) är en av de högst prioriterade psykosociala insatserna i Socialstyrelsens nationella riktlinjer. Utbildningen har gått regelbundet sedan 2012 och fokuserar nu även på Supported Education. Särskild tonvikt i utbildningen kommer att läggas vid implementeringen av IPS i b

https://www.medicin.lu.se/sites/medicin.lu.se/files/uppdragsutbildning_ips_ht_2020.pdf - 2026-05-17

The NanoLund newsletter is sent out 2–4 times a year, covering information about events, people, research, strategy, grants, and much more. The latest issue of the NanoLund Newsletter arrived in April 2026 Below, you can read previous NanoLund newsletters.April 2026December 2025October 2025June 2025April 2025December 2024October 2024June 2024April 2024December 2023November 2023June 2023March 2023D

https://www.nano.lu.se/about-nanolund/newsletters - 2026-05-15